Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Aihong Zhou is active.

Publication


Featured researches published by Aihong Zhou.


Alzheimers & Dementia | 2014

The prevalence of dementia in urban and rural areas of China

Jianping Jia; Fen Wang; Cuibai Wei; Aihong Zhou; Xiang-Fei Jia; Fang Li; Muni Tang; Lan Chu; Youlong Zhou; Chunkui Zhou; Yong Cui; Qi Wang; Weishan Wang; Peng Yin; Nan Hu; Xiumei Zuo; Haiqing Song; Wei Qin; Liyong Wu; Dan Li; Longfei Jia; Juexian Song; Ying Han; Yi Xing; Peijie Yang; Yuemei Li; Yuchen Qiao; Yi Tang; Jihui Lv; Xiumin Dong

The Chinese population has been aging rapidly and the countrys economy has experienced exponential growth during the past three decades. The goal of this study was to estimate the changes in the prevalence of dementia, Alzheimers disease (AD), and vascular dementia (VaD) among elderly Chinese individuals and to analyze differences between urban and rural areas.


Journal of Geriatric Psychiatry and Neurology | 2011

Montreal Cognitive Assessment in Detecting Cognitive Impairment in Chinese Elderly Individuals: A Population-Based Study

Jihui Lu; Dan Li; Fang Li; Aihong Zhou; Fen Wang; Xiumei Zuo; Xiang-Fei Jia; Haiqing Song; Jianping Jia

The Montreal Cognitive Assessment (MoCA) has been proved brief and sensitive to screen for mild cognitive impairment (MCI) and early dementia in some developed countries or areas. However, little MoCA data are available from mainland China. In this study, the MoCA was applied to 8411 Chinese community dwellers aged 65 or older (6283 = cognitively normal [CN], 1687 = MCI, and 441 = dementia). The MoCA norms were established considering significant influential factors. The optimal cutoff points were 13/14 for illiterate individuals, 19/20 for individuals with 1 to 6 years of education, and 24/25 for individuals with 7 or more years of education. With the optimal cutoffs, the sensitivity of the MoCA was 83.8% for all cognitive impairments, 80.5% for MCI and 96.9% for dementia, and the specificity for identifying CN was 82.5%. These indicate that with optimal cutoffs, the MoCA is valid to screen for cognitive impairment in elderly Chinese living in communities.


Alzheimers & Dementia | 2014

The prevalence of mild cognitive impairment and its etiological subtypes in elderly Chinese

Jianping Jia; Aihong Zhou; Cuibai Wei; Xiang-Fei Jia; Fen Wang; Fang Li; Xiaoguang Wu; Vincent Mok; Serge Gauthier; Muni Tang; Lan Chu; Youlong Zhou; Chunkui Zhou; Yong Cui; Qi Wang; Weishan Wang; Peng Yin; Nan Hu; Xiumei Zuo; Haiqing Song; Wei Qin; Liyong Wu; Dan Li; Longfei Jia; Juexian Song; Ying Han; Yi Xing; Peijie Yang; Yuemei Li; Yuchen Qiao

Epidemiologic studies on mild cognitive impairment (MCI) are limited in China.


Alzheimers & Dementia | 2016

The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: A multicentre, randomized, double-blind, placebo-controlled trial

Jianping Jia; Cuibai Wei; Junhua Liang; Aihong Zhou; Xiumei Zuo; Haiqing Song; Liyong Wu; Xiaochun Chen; Sheng-Di Chen; Junjian Zhang; Jiang Wu; Kai Wang; Lan Chu; Dantao Peng; Peiyuan Lv; Hongzhi Guo; Xiaoyuan Niu; Yingzhu Chen; Wanli Dong; Xiujie Han; Boyan Fang; Dan Li; Qian Jia; Liyuan Huang

Vascular cognitive impairment without dementia is very common among the aged and tends to progress to dementia, but there have been no proper large‐scale intervention trials dedicated to it. Vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease (hereinafter, subcortical Vascular cognitive impairment without dementia) represents a relatively homogeneous disease process and is a suitable target for therapeutic trials investigating Vascular cognitive impairment without dementia. Preclinical trials showed that dl‐3‐n‐butylphthalide (NBP) is effective for cognitive impairment of vascular origin.


American Journal of Alzheimers Disease and Other Dementias | 2012

Stage-Specific Gender Differences in Cognitive and Neuropsychiatric Manifestations of Vascular Dementia

Yi Xing; Cuibai Wei; Changbiao Chu; Aihong Zhou; Fang Li; Liyong Wu; Haiqing Song; Xiumei Zuo; Fen Wang; Wei Qin; Dan Li; Yi Tang; Xiang-Fei Jia; Jianping Jia

Studies on gender differences in the clinical manifestations of vascular dementia (VaD) are still lacking. In the present study, gender comparisons of cognitive and neuropsychiatric profiles were conducted separately for mild and moderate-to-severe VaD in a total of 467 patients with VaD. There were no significant gender differences in cognitive manifestations, except that females performed better on immediate verbal recall than males in mild stage. Women were more likely to exhibit delusions (15.5% vs 7.4%), hallucinations (9.5% vs 3.4%), and depression (43.1% vs 27.3%) in mild stage. The predominance of male patients was observed in apathy at moderate-to-severe stage (50.5% vs 34.8%). To conclude, gender differences existed in neuropsychiatric symptoms of VaD and were especially pronounced in mild stage. Delusions, hallucinations, and depression were more prevalent in females in mild VaD, with the male predominance only in apathy in the later stage.


Neurobiology of Aging | 2012

Exploration of 16 candidate genes identifies the association of IDE with Alzheimer's disease in Han Chinese

Fen Wang; Chang Shu; Longfei Jia; Xiumei Zuo; Yong-Biao Zhang; Aihong Zhou; Wei Qin; Haiqing Song; Cuibai Wei; Feng Zhang; Zhen Hong; Muni Tang; Duen-Mei Wang; Jianping Jia

Alzheimers disease (AD) has a complex pattern of inheritance and many genes have recently been reported to contribute to the disease susceptibility. We selected 106 SNPs within 16 candidate genes and performed a multistage association study using 4 sample sets consisting of 731 AD patients and 738 control subjects to identify genetic factors for AD in Han Chinese. A single nucleotide polymorphism (SNP) in the insulin degrading enzyme gene (IDE), rs3781239, showed a significant association with AD. The C allele increased the risk of AD 1.72-fold than the G allele (odds ratio [OR] = 1.72, 95% confidence interval [CI] = 1.17-2.53, p = 0.006) and CC carriers had a 4.89-fold higher risk for AD than that of the carriers with CG and GG genotypes (odds ratio = 4.89, 95% CI = 1.85-12.91, p = 0.001). Moreover, the CC genotype was significantly associated with earlier age at onset (p = 0.001, hazard ratio [HR] = 2.09, 95% CI = 1.38-3.18). Our data suggest that the polymorphism of IDE is associated with susceptibility to Alzheimers disease in Han Chinese.


Journal of Alzheimer's Disease | 2015

Elevated plasma angiogenesis factors in Alzheimer's disease.

Wei Qin; Xiang-Fei Jia; Fen Wang; Xiumei Zuo; Liyong Wu; Aihong Zhou; Dan Li; Baoquan Min; Cuibai Wei; Yi Tang; Yi Xing; Xiumin Dong; Qi Wang; Yining Gao; Ying Li; Jianping Jia

Evidence has shown that aberrant angiogenesis is an integral part of Alzheimers disease (AD). Angiogenesis is a complex process requiring successive activation of a rather large series of factors. The aim of this study was to determine which angiogenesis molecule(s) abnormalities were changed in plasma of AD subjects and whether plasma levels of angiogenesis factors were associated with cognitive function and risk of AD. Discovery-phase antibody arrays were used to detect plasma concentrations of 55 angiogenesis-related factors. Enzyme-linked immunosorbent assays (ELISAs) in a large cohort were further performed to identify the association of plasma angiogenesis factors with AD. We found that plasma angiogenin (ANG) and tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) levels were higher in patients with AD than those in normal subjects. Significantly higher ANG and TIMP-4 were observed in the severe AD group relative to the mild AD. There were different levels of plasma ANG and TIMP-4 compared with vascular dementia and other dementias. Age or gender had no major effects on levels of these proteins. Plasma ANG and TIMP-4 levels tended to be higher in ApoE ε4 carriers compared with non-carriers, but not significantly. A multiple regression analysis after adjusting for covariates revealed correlations between plasma ANG and TIMP-4 and the MMSE and CDR. Higher plasma ANG and TIMP-4 levels were associated with significant AD risk. These results demonstrate that plasma ANG and TIMP-4 may reflect the severity of cognitive function impairment, and higher levels were associated with risk of AD.


Evidence-based Complementary and Alternative Medicine | 2015

The Effects of Acupuncture at Real or Sham Acupoints on the Intrinsic Brain Activity in Mild Cognitive Impairment Patients

Baohui Jia; Zhishun Liu; Baoquan Min; Zhenchang Wang; Aihong Zhou; Yong-Yong Li; Haifa Qiao; Jianping Jia

Accumulating neuroimaging studies in humans have shown that acupuncture can modulate a widely distributed brain network in mild cognitive impairment (MCI) and Alzheimers disease (AD) patients. Acupuncture at different acupoints could exert different modulatory effects on the brain network. However, whether acupuncture at real or sham acupoints can produce different effects on the brain network in MCI or AD patients remains unclear. Using resting-state fMRI, we reported that acupuncture at Taixi (KI3) induced amplitude of low-frequency fluctuation (ALFF) change of different brain regions in MCI patients from those shown in the healthy controls. In MCI patients, acupuncture at KI3 increased or decreased ALFF in the different regions from those activated by acupuncture in the healthy controls. Acupuncture at the sham acupoint in MCI patients activated the different brain regions from those in healthy controls. Therefore, we concluded that acupuncture displays more significant effect on neuronal activities of the above brain regions in MCI patients than that in healthy controls. Acupuncture at KI3 exhibits different effects on the neuronal activities of the brain regions from acupuncture at sham acupoint, although the difference is only shown at several regions due to the close distance between the above points.


Journal of Alzheimer's Disease | 2017

Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer’s Disease: A Randomized Controlled Trial

Jianping Jia; Cuibai Wei; Longfei Jia; Yi Tang; Junhua Liang; Aihong Zhou; Fangyu Li; Lu Shi; Rachelle S. Doody

BACKGROUND Donepezil has been used worldwide for the treatment of severe Alzheimers disease (AD). Whether it is also appropriate for severe AD in Chinese patients remains unknown. OBJECTIVE To determine whether donepezil is effective and tolerable for Chinese patients with severe AD. METHODS The present study was a 24-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study conducted at 38 investigational hospitals in China. Patients with severe AD were enrolled in this trial. Patients were randomly assigned in a 1:1 ratio to receive either donepezil or placebo (5 mg for 6 weeks and10 mg for the remaining 18 weeks). The efficacy for donepezil were evaluated by the SIB, the Clinicians Interview-Based Impression of Change-Plus caregiver input (CIBIC-plus) and the MMSE. Safety parameters were monitored throughout. RESULTS A total of 313 patients included the donepezil (n = 157) and the placebo groups (n = 156). Donepezil group improved more in SIB scores (least squares [LS] mean difference: 4.8, 95% CI 1.56 to 8.08, p = 0.004) and CIBIC-plus scores (drug-placebo difference: -0.4, 95% CI -0.66 to 0.03, p = 0.04) than placebo groups at Week 24. The MMSE scores between drug and placebo groups did not differ significantly. Twenty-nine patients with serious adverse events (SAEs) were reported in donepezil (n = 11) and placebo groups (n = 18) (p = 0.08). Most SAEs were not considered drug-related. CONCLUSION Donepezil for 24 weeks was more effective than placebo and showed good safety and tolerability in Chinese patients with severe AD. This study supports utility of the drug in severe stages of AD in the Chinese population.


Alzheimers & Dementia | 2018

The cost of Alzheimer's disease in China and re-estimation of costs worldwide

Jianping Jia; Cuibai Wei; Shuoqi Chen; Fangyu Li; Yi Tang; Wei Qin; Lina Zhao; Hongmei Jin; Hui Xu; Fen Wang; Aihong Zhou; Xiumei Zuo; Liyong Wu; Ying Han; Yue Han; Liyuan Huang; Qi Wang; Dan Li; Changbiao Chu; Lu Shi; Min Gong; Yifeng Du; Jiewen Zhang; Junjian Zhang; Chunkui Zhou; Jihui Lv; Yang Lv; Haiqun Xie; Yong Ji; Fang Li

The socioeconomic costs of Alzheimers disease (AD) in China and its impact on global economic burden remain uncertain.

Collaboration


Dive into the Aihong Zhou's collaboration.

Top Co-Authors

Avatar

Jianping Jia

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Cuibai Wei

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Fen Wang

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Xiumei Zuo

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Liyong Wu

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Dan Li

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Wei Qin

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Haiqing Song

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Yi Tang

Capital Medical University

View shared research outputs
Top Co-Authors

Avatar

Qi Wang

Capital Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge